Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

CROs look to buttress research models businesses with CRISPR/Cas tech

As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’ research models.

Ergomed bolsters post-marketing biz through acquisition

UK-based CRO Ergomed has acquired medical information firm Sound Opinion as a boost to its post-marketing services.

Intertek opens new drug stability testing facility citing demand and bigger med devices

Intertek has opened a new stability facility citing demand for bespoke drug and device services like abuse potential assessments and stress testing.

Quintiles maintains 'outperform' rating following recent flurry of activity

A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

EMA re-confirms drug suspensions due to faulty trial data from GVK Biosciences

Following a re-examination requested by MAHs (marketing authorisation holders) for seven of the medicines suspended, the EMA has re-confirmed its recommendation to suspend hundreds of drugs following issues with clinical studies conducted at CRO GVK Biosciences in Hyderabad, India. 

House introduces companion bill to offer CROs a share of R&D tax credit

In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...